Freestone Capital Holdings LLC Decreases Position in Zimmer Biomet Holdings, Inc. (ZBH)

Freestone Capital Holdings LLC cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,314 shares of the medical equipment provider’s stock after selling 111 shares during the period. Freestone Capital Holdings LLC’s holdings in Zimmer Biomet Holdings were worth $1,324,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Los Angeles Capital Management & Equity Research Inc. lifted its position in Zimmer Biomet Holdings by 99.6% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 9,942 shares of the medical equipment provider’s stock valued at $1,277,000 after purchasing an additional 4,960 shares in the last quarter. Armor Investment Advisors LLC lifted its position in Zimmer Biomet Holdings by 2.0% during the second quarter. Armor Investment Advisors LLC now owns 2,600 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 50 shares in the last quarter. Timber Hill LLC purchased a new position in shares of Zimmer Biomet Holdings in the second quarter valued at about $238,000. Synovus Financial Corp lifted its position in shares of Zimmer Biomet Holdings by 6.3% in the second quarter. Synovus Financial Corp now owns 2,288 shares of the medical equipment provider’s stock valued at $293,000 after acquiring an additional 135 shares in the last quarter. Finally, Bradley Foster & Sargent Inc. CT lifted its position in shares of Zimmer Biomet Holdings by 21.2% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 18,318 shares of the medical equipment provider’s stock valued at $2,352,000 after acquiring an additional 3,205 shares in the last quarter. Institutional investors own 85.48% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down 0.86% during mid-day trading on Friday, hitting $114.99. The stock had a trading volume of 622,981 shares. The firm has a market cap of $23.25 billion, a PE ratio of 32.75 and a beta of 1.21. The stock’s 50-day moving average is $115.16 and its 200 day moving average is $120.75. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by ($0.02). The company had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. Zimmer Biomet Holdings’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.02 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

In other news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.07% of the company’s stock.

Several brokerages have recently commented on ZBH. Royal Bank Of Canada restated an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, June 30th. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $135.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $136.75.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/freestone-capital-holdings-llc-sells-111-shares-of-zimmer-biomet-holdings-inc-zbh/1603681.html.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.